Health Affairs December 14, 2022
Nitzan Arad, Mark B. McClellan

The Inflation Reduction Act (“IRA”), signed by President Biden on August 16, 2022, is the most substantial drug payment and coverage legislation enacted since the Medicare Modernization Act of 2003, which created Medicare Part D and made important changes to the way physician-administered drugs are reimbursed in Medicare Part B. Due to the budget reconciliation process requiring a direct impact on the Federal budget or revenue, provisions related to commercial markets were struck from the final version of the IRA, and thus its drug pricing provisions pertain directly only to Medicare. But the law’s effects will extend system-wide because of the sheer size of Medicare as a health purchaser and because of the relationship its pricing requirements have with other...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Healthcare System, HHS, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article